Gyre Therapeutics (GYRE) has received a new Buy rating, initiated by H.C. Wainwright analyst, Matthew Keller.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Keller has given his Buy rating due to a combination of factors that highlight the potential of Gyre Therapeutics’ lead asset, hydronidone. This drug, a structural analog of pirfenidone, is a potent inhibitor of fibrosis, particularly targeting the transforming growth factor beta (TGF-β) pathway in the liver. It has shown promising safety and efficacy in late-stage clinical trials for chronic hepatitis-B associated liver fibrosis in China and is expected to enter Phase 2 clinical trials for MASH and liver fibrosis in the U.S. by the second half of 2025.
Moreover, Gyre Therapeutics has a robust portfolio of clinical and commercial stage therapies targeting fibrosis and related inflammatory conditions, which adds to its attractiveness. Despite the significant unmet clinical need and commercial opportunity in treating liver fibrosis, Gyre’s potential remains underappreciated by investors. Keller believes that the company’s established therapeutics and the significant upside potential of its stock make it a compelling investment opportunity, with hydronidone potentially becoming a blockbuster drug with estimated annual sales of approximately $6 billion in the U.S. by 2033.